On this site you will find clinical studies with cannabis or single
cannabinoids in different diseases and case reports on the use of cannabis by
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.
|Title||Effects of tetrahydrocannabinol on balance and gait in patients with dementia: A randomised controlled crossover trial.|
|Author(s)||van den Elsen GA, Tobben L, Ahmed AI, Verkes RJ, Kramers C, Marijnissen RM, Olde Rikkert MG, van der Marck MA.|
|Journal, Volume, Issue||J Psychopharmacol. 2016 Sep 13. pii: 0269881116665357. [Epub ahead of print]|
|Major outcome(s)||No differences in the number and type of adverse events were found, and no falls occurred after administration of THC.|
Oral tetrahydrocannabinol (THC) is currently studied for its possible efficacy on dementia-related neuropsychiatric symptoms (NPS), but might lead to increased risk of falling. This was a randomised, double-blind, crossover study to evaluate the effects of THC on mobility in dementia patients. Eighteen community-dwelling patients (Mage=77 years) received 1.5 mg of oral THC twice daily and placebo, in random order, for three days, separated by a four-day washout. Balance and gait were assessed using SwayStar(TM) and GAITRite(TM) within two hours after administration, in two consecutive intervention periods, under the following conditions: standing with eyes open (EO) and eyes closed (EC), preferred speed walking with and without a cognitive dual task. THC significantly increased sway during standing EC (roll angle 0.32[±0.6]°, p=0.05; pitch angle 1.04[±1.5]°, p=0.009; pitch velocity 1.96[±3.3]°/s, p=0.02), but not during standing EO. During preferred speed walking, THC increased stride length (4.3[±5.4] cm, p=0.005) and trunk sway (pitch angle 1.18[±1.6]°, p=0.005). No effects were observed during dual task walking. No differences in the number and type of adverse events were found, and no falls occurred after administration of THC. This study showed that 3 mg of THC per day has a benign adverse event profile regarding mobility and was well tolerated by community-dwelling dementia patients.
|Dose(s)||1.5 mg THC twice daily|
|Participants||18 patients with dementia|
|Type of publication||Medical journal|
|Address of author(s)||Radboudumc Alzheimer Centre and Department of Geriatric Medicine Geke.vandenElsen@radboudumc.nl.|